Trial Profile
Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2018
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 24 Sep 2018 Status changed from suspended to withdrawn prior to enrolment.
- 24 Sep 2018 Planned End Date changed from 1 Mar 2014 to 2 Nov 2010.
- 24 Sep 2018 Planned primary completion date changed from 1 Mar 2014 to 2 Nov 2010.